Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

Rhea-AI Summary

Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its first quarter 2025 financial results announcement for May 6, 2025, at 8:00 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Investors can participate through:

• U.S. dial-in: (800)-836-8184
• International dial-in: (646)-357-8785
• Live audio webcast: Available on the Curis website's events & presentations section

Emavusertib, their key drug candidate, is an oral small molecule IRAK4 inhibitor. A replay of the conference call will be accessible at www.curis.com.

Positive

• Curis maintains its NASDAQ listing status (CRIS)
• Company continues development of emavusertib, a key IRAK4 inhibitor drug candidate

Negative

• No preliminary financial results provided ahead of the earnings call
• Focus on single drug candidate (emavusertib) suggests limited pipeline diversity

LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the events & presentations section of the Curis website. A replay of the conference call will be available at www.curis.com.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-first-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-6-2025-302441183.html

SOURCE Curis, Inc.

FAQ

When will Curis (CRIS) release Q1 2025 earnings?

Curis (CRIS) will release its Q1 2025 financial results on Tuesday, May 6, 2025, at 8:00 a.m. ET, followed by a conference call at 8:30 a.m. ET.

How can investors join Curis (CRIS) Q1 2025 earnings call?

Investors can join by dialing (800)-836-8184 from the US or (646)-357-8785 internationally. A live audio webcast will also be available on the Curis website's events & presentations section.

What is Curis (CRIS) main drug development focus?

Curis is developing emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor as their main drug candidate.

Where can I find the replay of Curis (CRIS) Q1 2025 earnings call?

A replay of the conference call will be available at www.curis.com after the live event.

What time is Curis (CRIS) Q1 2025 earnings webcast?

The earnings webcast will begin at 8:30 a.m. ET on Tuesday, May 6, 2025, following the financial results release at 8:00 a.m. ET.